BSG and cancer: Furthermore, the subgroup analysis of tumors stratified by cancer type also demonstrated a significant association between higher CD147/EMMPRIN expression and adverse outcome of OS for breast carcinoma (meta-HR = 2.92; 95% CI: 1.85–4.60), bladder cancer (meta-HR = 2.32; 95% CI: 1.63–3.29), colorectal cancer (meta-HR = 2.14; 95% CI: 1.38–4.26), ovarian cancer (meta-HR = 1.57; 95% CI: 1.23–2.01) and osteosarcoma (meta-HR = 7.83; 95% CI: 3.18–19.27) in the multivariate model.